I. Drugs that contain chemicals taken directly from the marijuana plant
	Name/Trade Name	Manufacturer	Approval Status	Suggested Medical Use	Cannabis-Related Properties
1.	Sativex	GW Pharmaceuticals	U.S. Phase III clinical trials started in late 2006 Approved for use in Canada (2005) and Catalonia, Spain (2005); Licensed to Bayer in the UK and to Almirall in Europe GW Pharmaceuticals to submit an application for UK licensing in late 2008	Treatment of neuropathic pain and spasticity in patients with Multiple Sclerosis (MS); Analgesic treatment in adult patients with advanced cancer who experience moderate to severe pain.	Mouth spray whose chemical compound is derived from natural extracts of the cannabis plant

II. Drugs that contain synthetic versions of chemicals naturally found in marijuana
	Name/Trade Name	Manufacturer	Approval Status	Suggested Medical Use	Cannabis-Related Properties
1.	Dronabinol/ Marinol	Unimed Pharmaceuticals, a subsidiary of Solvay Pharmaceuticals	FDA approved in United States as an appetite stimulant (1992) and for nausea (1985) Approved in Denmark for multiple sclerosis (Sep. 2003) Approved in Canada for AIDS-related anorexia (Apr. 2000) and for nausea and vomiting associated with cancer chemotherapy (1988)	Treatment of nausea and vomiting for patients in cancer treatment; Appetite stimulant for AIDS patients; Analgesic to ease neuropathic pain in multiple sclerosis patients	Synthetic Delta-9 THC
2.	Dronabinol Metered Dose Inhaler (MDI)/ Marinol aerosol	Solvay Pharmaceuticals	Not approved for use as of Feb. 15, 2008 Phase II clinical trials in the United States completed Sep. 7, 2006	Treatment of nausea, vomiting, migraines, spasticity in MS patients, and neuropathic pain	Human-made THC inhaler

III. Drugs that contain chemicals similar to those in marijuana but not found in the plant
	Name/Trade Name	Manufacturer	Approval Status	Suggested Medical Use	Cannabis-Related Properties
1.	Nabilone/ Cesamet	Valeant Pharmaceuticals International	Approved for use in the United States (1985), United Kingdom and Australia (1982), Canada (1981) On May 15, 2006, the FDA approved safety labeling revisions for nabilone (Cesamet 1-mg capsules) to advise of warnings and precautions related to its use in the treatment of chemotherapy-related nausea and vomiting	Treatment of nausea and vomiting in patients undergoing cancer treatment	Synthetic cannabinoid similar to THC
2.	Dexanabinol	Pharmos	Not approved for use as of Feb. 15, 2008 The Phase III clinical trial involving 846 patients was completed in Dec. 2004; Pharmos said the drug failed to show statistically significant improvement in the late-stage clinical trial	Neuroprotective (protects brain from damage) for use after cardiac surgery Regain memory and other high-level function following Traumatic Brain Injury (TBI)	Synthetic non-psychotropic cannabinoid which blocks NMDA receptors and COX-2 cytokines and chemokines
3.	CT-3 (ajulemic acid)	Atlantic Technology Ventures	Not approved for use as of Feb. 15, 2008 Completed Phase I clinical trials as of July 2002 Phase II study began in May 2002 in Germany to test its analgesic properties in patients with neuropathic pain	Treatment of spasticity and neuropathic pain in MS patients	Synthetic, more potent analog of THC metabolite THC-11-oic acid
4.	PRS-211,375/ Cannabinor and Cannabinor Oral	Pharmos	Not approved for use as of Feb. 15, 2008 Phase II(a) trials began in the 2nd quarter of 2006 and continued as of Apr. 2007 In Jan. 2007, Pharmos reported that in a Phase 2a experimentally induced pain model, cannabinor failed to meet the primary endpoint of reducing capsaicin-induced pain	Anti-inflammatory Treatment of pain	Synthetic chemical that specifically binds to the brain's secondary cannabinoid receptor (CB2)
5.	HU 308	Pharmos (licensed from the Hebrew University of Jerusalem)	Not approved for use as of Feb. 15, 2008 Demonstrated efficacy in pre-clinical laboratory studies	Treatment of hypertension Anti-inflammatory	Synthetic chemical that specifically binds to the brain's secondary cannabinoid receptor (CB2)
6.	HU 331	Cayman Chemical	Not approved for use as of Feb. 15, 2008 Demonstrated efficacy in pre-clinical laboratory studies, and has finished pre-clinical toxicology studies ProCon.org contacted Cayman Chemical by phone on Feb. 15, 2008; According to Cayman Chemical, no current studies were taking place although HU 331 was available for purchase by research institutions Demonstrated efficacy in pre-clinical laboratory studies	Treatment of memory, weight loss, appetite, neurodegeneration, tumor surveillance, analgesia, and inflammation	Synthetic chemical compound composed of central cannabinoid (CB1), peripheral cannabinoid (CB2), and non-CB receptor-mediated pharmacology

IV. Drugs that do not work like marijuana but use the same brain pathways
	Name/Trade Name	Manufacturer	Approval Status	Suggested Medical Use	Cannabis-Related Properties
1.	Rimonabant/ Acomplia	Sanofi-Aventis	Not approved for use as of Feb. 15, 2008 On June 13, 2007, an FDA advisory panel of outside experts unanimously recommended that the regulatory agency not approve the drug for sale in the United States Sanofi-Aventis withdrew its FDA application following the rejection, but announced that they will re-submit rimonabant to the FDA at a future date Approved in June 2006 for use in Europe, marketed in 18 countries; Also available in Argentina, Brazil, and Mexico	Anti-obesity	Synthetic chemical that blocks endocannabinoids from being received in the brain, and, as a result, suppresses appetite.
2.	Taranabant/ MK-0364	Merck	Not approved for use as of Feb. 15, 2008 Merck is expected to submit the drug for FDA approval in 2008 In Phase III trials as of Jan. 8, 2008	Anti-obesity	Targets receptors in the brain linked to appetite. Acts as a Cannabinoid receptor type 1 (CB1R) inverse agonist, blocking cannabinoid receptors in the brain, which suppresses appetite
2.	URB597 or KDS-4103	Cayman Chemical and Kadmus Pharmaceuticals Inc	Not approved for use as of Feb. 15, 2008 Demonstrated efficacy in pre-clinical laboratory studies, and has finished pre-clinical toxicology studies ProCon.org contacted Cayman Chemical by phone on Feb. 15, 2008; According to Cayman Chemical, no current studies were taking place although URB597 was available for purchase by research institutions	Treatment of pain (acute - post-surgical; inflammatory - arthritis; neuropathic - damaged nerve cells from shingles, H.I.V., diabetes), anxiety, and depression	Increases the amount of endocannabinoids in the brain by blocking the natural process of deactivating them. The same process that deactivates endocannabinoids also blocks chemicals which regulate mood
3.	O-3246	Not available	Not approved for use as of Feb. 15, 2008 Demonstrated efficacy in pre-clinical laboratory studies	Treatment of spasticity in MS patients	Increases the amount of anandamide, an endocannabinoid, by tricking the brain to produce more instead of uptaking what is already present
4.	AM 281	Bachem (formerly Peninsula Laboratories)	Not approved for use as of Feb. 15, 2008 Demonstrated efficacy in pre-clinical laboratory studies	Neuroprotective for use in association with septic shock	Synthetic chemical that blocks the endocannabinoids from being received in the brain, regulating the flow of blood to the brain during septic shock